STOCK TITAN

Opus Genetics (IRD) Financials

IRD NASDAQ

Ticker history: OCUP became IRD (Opus Genetics, Inc.) on . Earlier news and filings retain their original names and dates. View OCUP history.

Trailing 12 months to September 30, 2026
Revenue $7.9M -45.9% YoY
Net Income -$136.7M n/m YoY
EPS (Diluted) -$1.56 YoY not available
Operating Cash Flow -$48.5M n/m YoY
Market Cap $378.9M as of Nov 18, 2026
Price / Sales 47.9x on $7.9M revenue, trailing 12 months to September 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 9.9x on $38.4M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 18, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IRD SEC filings page.

Opus Genetics, Inc. (IRD) reported $7.9M in revenue over the twelve months to Sep 30, 2026, down 45.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI IRD FY2025

Opus remains a development-stage business: research spending exceeds revenue, while financing—not operations—supplies its cash.

The net loss was $49.6M versus an operating cash outflow of $35.3M, so accounting losses were not a one-for-one cash charge during FY2025. Yet operating cash outflow widened from $1.1M in FY2023 to $35.3M in FY2025, showing that the underlying cash burden intensified even as the accounting loss improved from FY2024.

FY2025 R&D reached $30.8M against revenue of $14.2M, so the reported business is organized around development investment rather than current sales. R&D rose 14.8% while revenue rose 29.1%, indicating that revenue recovery has not yet changed the company’s investment-heavy operating structure.

Financing cash flow provided $50.0M in FY2025, while equity stood at $15.3M; external financing, rather than operating earnings, was the main source supporting the balance sheet. Reported liquidity equaled 15.3 months of the latest annual operating outflow, but a current ratio of 6.4x coexisted with liabilities equal to 69.5% of assets, separating near-term liquidity from overall capitalization.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Cash Runway Dilution R&DIntensity Revenue Progress BurnTrend BalanceSheet 39 / 100
Financial Health Score 39/100
Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Opus Genetics, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway
42

Opus Genetics, Inc. held $45.1M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $35.3M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Opus Genetics, Inc. scores 42/100 among other emerging companies.

Dilution
18

Dilution ranks emerging companies on the yearly rate at which their shares outstanding grew across the last three fiscal years (the last two where the earliest reports none), a slower rise ranking higher because each round of funding spreads the same business across more owners. Opus Genetics, Inc. scores 18/100 on it among other emerging companies.

R&D Intensity
79

Opus Genetics, Inc. spent $30.8M on research and development in fiscal year 2025, which was 58.4% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Opus Genetics, Inc. scores 79/100 among other emerging companies.

Revenue Progress
26

Revenue Progress ranks emerging companies on the yearly rate at which their revenue compounded across the last three fiscal years (the last two where the earliest reports none), counted in the currency each company reports in. Opus Genetics, Inc. scores 26/100 on it among other emerging companies.

Burn Trend
1

Burn Trend ranks emerging companies on how far their operating cash flow moved between the newest fiscal year and the one two years earlier, measured against the cash the earlier year used, and a move toward generating cash ranks higher. Opus Genetics, Inc. scores 1/100 on it among other emerging companies.

Balance Sheet
66

Opus Genetics, Inc.'s cash, cash equivalents and investments came to $45.1M at the end of fiscal year 2025, against $34.9M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Opus Genetics, Inc. scores 66/100 among other emerging companies.

Altman Z-Score Distress
0.02

Opus Genetics, Inc. scores 0.02, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $188.6M against total assets of $50.2M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
3/8

Opus Genetics, Inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) does not pass.

Earnings Quality No Cash Backing
N/A

Opus Genetics, Inc. reported a net loss of $49.6M while operations used $35.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Opus Genetics, Inc. reported an operating loss of $38.6M against $129K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$1.1M
YoY-63.1%
QoQ+50.6%

Opus Genetics, Inc. generated $1.1M in revenue in Q3 2026. This represents a decrease of 63.1% from the same quarter a year earlier. Against the prior quarter it is up 50.6%.

EBITDA
-$19.2M
YoYn/m
QoQn/m

Opus Genetics, Inc.'s EBITDA was -$19.2M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$46.5M
YoYn/m
QoQn/m
5Y CAGRn/m

Opus Genetics, Inc. reported a net loss of $46.5M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.46
YoYn/m
QoQn/m

Opus Genetics, Inc. earned -$0.46 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Cash & Debt
$89.0M
YoY+188.7%
QoQ+0.2%
5Y CAGR+31.9%
10Y CAGR+26.6%

Opus Genetics, Inc. held $89.0M in cash against $35.7M in long-term debt as of Q3 2026.

Shares Outstanding
97M
YoY+40.2%
QoQ+16.2%

Opus Genetics, Inc. had 97M shares outstanding in Q3 2026. This represents an increase of 40.2% from the same quarter a year earlier. Against the prior quarter it is up 16.2%.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-121.0%
YoY+171.5pp

Opus Genetics, Inc.'s quarterly ROE was -121.0% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 171.5 percentage points from the same quarter a year earlier.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

R&D Spending
$14.5M
YoY+126.2%
QoQ+29.3%
5Y CAGR+35.9%

Opus Genetics, Inc. invested $14.5M in research and development in Q3 2026. This represents an increase of 126.2% from the same quarter a year earlier. Against the prior quarter it is up 29.3%.

Share Buybacks

Not reported for Q3 2026.

Capital Expenditures

Not reported for Q3 2026.

IRD Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IRD quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$1.1M-63.1%$755K-73.8%$2.2M-50.6%$3.9M-10.2%$3.1M-20.4%$2.9M+159.2%$4.4M+155.4%$4.3M+154.4%
R&D Expenses$14.5M+126.2%$11.2M+86.1%$10.6M+33.0%$10.4M+48.3%$6.4M-28.6%$6.0M-1.1%$8.0M+67.5%$7.0M+83.1%
SG&A Expenses$5.9M+18.2%$6.0M+4.5%$5.9M-6.3%$4.9M-33.0%$5.0M+72.1%$5.8M+71.9%$6.3M+35.9%$7.3M+122.5%
Operating Income-$19.2Mn/m-$16.5Mn/m-$14.4Mn/m-$11.5Mn/m-$8.3Mn/m-$8.9Mn/m-$9.9Mn/m-$38.0Mn/m
EBITDA-$19.2Mn/m-$16.5Mn/m-$14.4Mn/m-$11.4Mn/m-$8.3Mn/m-$8.9Mn/m-$9.9Mn/m-$38.0Mn/m
Interest ExpenseN/AN/A$69Kn/mN/A$68Kn/mN/A$0N/A
Income Tax$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Net Income-$46.5Mn/m-$8.1Mn/m-$65.5Mn/m-$16.5Mn/m-$17.5Mn/m-$7.4Mn/m-$8.2Mn/m-$35.1Mn/m
EPS (Basic)-$0.46n/m-$0.08n/m-$0.75-$0.21-$0.25-$0.12-$0.24-$1.27
EPS (Diluted)-$0.46n/m-$0.14n/m-$0.75-$0.21-$0.25-$0.12-$0.24-$1.27
Diluted Shares (Avg)102M+44.2%111M+75.8%87MN/A71M63M34MN/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.

IRD Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IRD quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$95.3M+163.8%$93.0M+140.4%$66.8M+38.7%$50.2M+36.3%$36.1M-10.6%$38.7M-13.8%$48.2M-7.1%$36.9M-31.7%
Current Assets$94.9M+164.1%$92.7M+141.2%$66.6M+39.0%$50.0M+36.7%$35.9M-11.1%$38.4M-14.3%$47.9M-7.6%$36.6M-32.1%
Cash & Equivalents$89.0M+188.7%$88.8M+173.9%$60.0M+43.5%$45.1M+48.7%$30.8M-15.9%$32.4M-21.7%$41.8M-11.4%$30.3M-40.0%
Short-Term Investments$0n/m$0n/m$0-100.0%$0-100.0%$0-100.0%$0-100.0%$1K-80.0%$2K-86.7%
Accounts Receivable$1.0M-65.5%$1.0M-69.4%$1.7M-43.8%$2.0M-44.0%$2.9M+57.0%$3.4M+150.3%$3.1M+60.1%$3.6M+284.8%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$56.9M+88.6%$106.0M+400.0%$112.6M+161.3%$34.9M+15.8%$30.2M+395.2%$21.2M+404.8%$43.1M+644.7%$30.1M+645.6%
Current Liabilities$9.8M-66.2%$7.6M-62.3%$9.3M-61.5%$7.8M-31.1%$29.1M+377.7%$20.2M+381.0%$24.3M+319.1%$11.3M+179.4%
Non-Current Liabilities$47.0M+4303.7%$98.3M+9734.9%$103.3M+448.1%$27.1M+43.9%$1.1Mn/m$1.0Mn/m$18.8Mn/m$18.8Mn/m
Long-Term Debt$35.7M+3238.1%$35.3M+3428.1%$1.2M$1.1Mn/m$1.1M$1.0MN/A$0
Total Equity$38.4M+544.1%-$13.0M-174.3%-$45.8M-1003.5%$15.3M+128.3%$6.0M-82.6%$17.5M-57.0%$5.1M-89.0%$6.7M-86.5%
Retained Earnings-$308.7Mn/m-$262.2Mn/m-$254.1Mn/m-$188.6Mn/m-$172.1Mn/m-$154.6Mn/m-$147.2Mn/m-$139.0Mn/m

Not reported in any period shown, so not listed: Inventory, Goodwill.

IRD Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IRD quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$14.0Mn/m-$11.9Mn/m-$12.7Mn/m-$9.8Mn/m-$6.2Mn/m-$10.3Mn/m-$9.0Mn/m-$7.4M-263.5%
Depreciation & Amortization$22K+69.2%$14K0.0%$13K0.0%$13K+30.0%$13Kn/m$14Kn/m$13Kn/m$10K+233.3%
Stock-Based Compensation$1.6M+94.9%$1.4M+57.0%$1.5M+60.4%N/A$816K+5.2%$896K+11.2%$913K-7.3%N/A
Investing Cash Flow-$189Kn/m$0n/m$0n/m$0-100.0%$0n/m$0n/m$0n/m$1.2Mn/m
Financing Cash Flow$14.4M+216.7%$40.9M+4414.7%$27.6M+34.8%$24.1Mn/m$4.5M+1187.0%$906K-41.2%$20.5M+761.3%-$83K-102.3%

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.

IRD Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IRD quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Margin-1692.8%-2182.8%-665.9%-296.3%-269.9%-309.0%-227.2%-884.0%
Net Margin-4089.3%-1072.6%-3038.2%-427.5%-566.9%-257.5%-187.5%-816.7%
Return on Equity-121.0%+171.5ppN/AN/A-107.7%+414.9pp-292.5%-270.6pp-42.5%-23.4pp-161.5%-146.1pp-522.5%-512.9pp
Return on Assets-48.8%-0.5pp-8.7%+10.5pp-98.1%-81.1pp-32.9%+62.4pp-48.3%-29.7pp-19.2%-1.9pp-17.0%-3.3pp-95.3%-86.4pp
Current Ratio9.65+8.4x12.19+10.3x7.13+5.2x6.43+3.2x1.23-5.4x1.90-8.8x1.98-7.0x3.24-10.1x
Debt-to-Equity0.93+0.7xN/AN/A0.07+0.1x0.180.06N/A0.00
Liabilities-to-Equity1.48-3.6xN/AN/A2.27-2.2x5.05+4.9x1.21+1.1x8.49+8.4x4.48+4.4x
Asset Turnover0.01-0.1x0.01-0.1x0.03-0.1x0.080.0x0.090.0x0.070.0x0.09+0.1x0.12+0.1x

Not reported in any period shown, so not listed: Gross Margin, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Opus Genetics, Inc. IRD FY2025 $14.2M -$49.6M N/A $378.9M 39/100
MapLight Therapeutics, Inc. MPLT FY2025 N/A -$161.2M N/A $373.8M —
Contineum Therapeutics, Inc. CTNM FY2025 N/A -$60.0M N/A $362.8M —
Neurogene, Inc. NGNE FY2025 $0 -$90.4M N/A $479.0M —
Avalo Therapeutics, Inc. AVTX FY2025 $59K -$78.3M N/A $387.4M —
Oculis Holding AG OCS FY2025 $1.5M -$124.7M N/A $411.7M 62/100

Frequently Asked Questions

Opus Genetics, Inc. (IRD) reported $14.2M in total revenue for fiscal year 2025. This represents a 29.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Opus Genetics, Inc. (IRD) revenue grew by 29.1% year-over-year, from $11.0M to $14.2M in fiscal year 2025.

No, Opus Genetics, Inc. (IRD) reported a net loss of $136.7M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $49.6M.

Opus Genetics, Inc. (IRD) reported diluted earnings per share of -$0.80 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Opus Genetics, Inc. (IRD) had EBITDA of -$38.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, Opus Genetics, Inc. (IRD) had $45.1M in cash and equivalents against $1.1M in long-term debt.

Opus Genetics, Inc. (IRD) has a return on equity of -323.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Opus Genetics, Inc. (IRD) recorded an outflow of $35.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Opus Genetics, Inc. (IRD) had $50.2M in total assets as of fiscal year 2025, including both current and long-term assets.

Opus Genetics, Inc. (IRD) invested $30.8M in research and development during fiscal year 2025.

Opus Genetics, Inc. (IRD) had 71M shares outstanding as of fiscal year 2025.

Opus Genetics, Inc. (IRD) had a current ratio of 6.43 as of fiscal year 2025, which is generally considered healthy.

Opus Genetics, Inc. (IRD) had a debt-to-equity ratio of 0.07 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

Opus Genetics, Inc. (IRD) had a liabilities-to-equity ratio of 2.27 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

Opus Genetics, Inc. (IRD) had a return on assets of -98.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Opus Genetics, Inc. (IRD) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $378.9M as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Opus Genetics, Inc. (IRD) trades at 47.9x sales, its market capitalization divided by $7.9M revenue, trailing 12 months to September 30, 2026. The market capitalization is $378.9M as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Opus Genetics, Inc. (IRD) held $45.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $35.3M over that year. Dividing the one by the other, the reported balance equals about 15 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Opus Genetics, Inc. (IRD) has an Altman Z-Score of 0.02, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Opus Genetics, Inc. (IRD) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Opus Genetics, Inc. (IRD) reported a net loss of $49.6M while operations used $35.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Opus Genetics, Inc. (IRD) reported an operating loss of $38.6M against $129K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Opus Genetics, Inc. (IRD) scores 39 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top